Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Danny Deckard

Physician Assistant, Medical Dallas, TX Physician Assistant

NPI 1386973451 CMS profile 11022920

3500 Oak Lawn, Ste 600, Dallas, TX 75219

Open in the dashboard

General payments

$100,648

443 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Danny Deckard of Dallas, TX is reported in the CMS Open Payments database as having received $100,648 across 443 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $4,009 4
2023 General $48,042 194
2022 General $28,158 117
2021 General $20,439 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danny Deckard
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Danny Deckard were reported at $0. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Danny Deckard Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $20,439 $156 $41–$563 $132
2022 $28,158 $185 $55–$649 $149
2023 $48,042 $199 $58–$717 $160
2024 $4,009 $206 $62–$740 $164
2025 $0 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. ViiV Healthcare Company $38,637 145 payments
  2. Gilead Sciences, Inc. $36,419 134 payments
  3. EMD Serono, Inc. $8,174 18 payments
  4. Merck Sharp & Dohme Corporation $7,862 27 payments
  5. Janssen Scientific Affairs, LLC $5,714 6 payments
  6. Janssen Products, LP $1,156 3 payments
  7. Theratechnologies Inc. $919 9 payments
  8. Novo Nordisk Inc $279 24 payments
  9. Janssen Biotech, Inc. $228 15 payments
  10. AstraZeneca Pharmaceuticals LP $163 4 payments
  11. Other $1,094 58 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $73,828 65 payments
  2. Travel and Lodging $14,618 53 payments
  3. Food and Beverage $7,896 320 payments
  4. Consulting Fee $4,190 3 payments
  5. Education $116 2 payments
Products named General payments · program years 2021–2024
  1. Descovy $21,582 47 payments
  2. APRETUDE $18,136 49 payments
  3. DOVATO $17,586 71 payments
  4. Biktarvy $9,807 25 payments
  5. Serostim $8,045 10 payments
  6. SYMTUZA $7,099 24 payments
  7. PIFELTRO $6,088 18 payments
  8. DELSTRIGO $1,817 11 payments
  9. CABENUVA $1,440 26 payments
  10. TROGARZO $919 9 payments
  11. Other $2,337 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

153

Median for Physician Assistant: 241

Drug cost

$122,322

Median for Physician Assistant: $4,110

Branded share of claims

31.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 21 $84,288
Descovy Emtricitabine/Tenofov Alafenam Brand 15 $36,750
Atorvastatin Calcium Generic 34 $353
Trazodone Hcl Generic 34 $279
Bupropion Xl Bupropion Hcl Brand 12 $260
Mirtazapine Generic 12 $173
Rosuvastatin Calcium Generic 13 $151
Anastrozole Generic 12 $69

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Serostim
  • EMD Serono, Inc. $3,995
$3,995 — —
NURTEC ODT
  • PFIZER INC. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

443 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record